IPI-145 Shows Promise in CLL Patients.
In Cancer Discov, 28 Feb 2014
Results from a phase I study of Infinity Pharmaceuticals' IPI-145, which inhibits both δ and γ isoforms of phosphoinositide3-kinase, suggest the drug is safe and effective in patients with advanced chronic lymphocytic leukemia.
Noncanonical NF-κB Signaling Is Limited by Classical NF-κB Activity.
Philadelphia, United States. In Sci Signal, Dec 2013
The classical pathway requires inhibitor of κB kinase β (IKKβ) and NF-κB essential modulator (NEMO), and hypomorphic mutations in the gene encoding NEMO (ikbkg) lead to inherited immunodeficiencies, collectively termed NEMO-ID.
Genetic background of nonsyndromic oligodontia: a systematic review and meta-analysis.
Gießen, Germany. In J Orofac Orthop, Jul 2013
All these genes vary both in terms of number of identified mutations and in terms of number of documented patients: 33 mutations and 93 patients are on record for PAX9, 10 mutations and 51 patients for EDA, 12 mutations and 33 patients for MSX1, 6 mutations and 17 patients for AXIN2, and 1 mutation in 1 patient for EDARADD, NEMO, and KRT17 each.